(Q38057736)

27 August 2017

title

Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond (English)

1 reference

obsessive-compulsive disorder

27 August 2017

0 references

1 reference

Naomi A Fineberg

1

1 reference

27 August 2017

Samar Reghunandanan

series ordinal

2

1 reference

27 August 2017

Angus Brown

series ordinal

3

1 reference

27 August 2017

Ilenia Pampaloni

series ordinal

4

1 reference

27 August 2017

publication date

2 November 2012

1 reference

Australian and New Zealand Journal of Psychiatry

27 August 2017

published in

1 reference

27 August 2017

volume

47

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

121-141

1 reference

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quetiapine Addition in Obsessive-Compulsive Disorder: Is Treatment Outcome Affected by Type and Dose of Serotonin Reuptake Inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

The treatment of severe, chronic, resistant obsessive-compulsive disorder. An evaluation of an in-patient programme using behavioural psychotherapy in combination with other treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Specific aspects of erectile dysfunction in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Escitalopram prevents relapse of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Predictors and Moderators of Treatment Outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Obsessive-compulsive disorder and serotonin: is there a connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

The improvement of obsessive- compulsive symptoms in a patient with schizophrenia treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Fluoxetine in children and adolescents with OCD: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Citalopram for treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Memantine augmentation for refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Nicotine augmentation for refractory obsessive-compulsive disorder. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Cognitive-behavioral therapy for children who have obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Riluzole in the treatment of mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A single-blinded case-control study of memantine in severe obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

High doses of sertraline for treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

Obsessive-compulsive severity spectrum in the community: prevalence, comorbidity, and course

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0004867412461958

21 January 2018

Identifiers

DOI

10.1177/0004867412461958

1 reference

27 August 2017

1 reference